Monday, January 24, 2022– Arlington, VA– The Digital Therapeutics Alliance (DTA) is leading the next phase of industry growth and impact by convening leaders and stakeholders to establish consistent and scalable frameworks for the assessment, integration, and adoption of digital therapeutic (DTx) products.
As a part of this work, DTA published overviews for DTx regulatory and reimbursement pathways in eight countries: Australia, China, France, Germany, Japan, South Korea, United Kingdom, and United States. These publications provide a snapshot of currently available pathways within each market. Recognizing the significant progress these countries have made to develop DTx frameworks, DTA looks forward to the continued maturation of these pathways and will regularly update each document to reflect ongoing changes within national systems.
“Digital therapeutics are increasingly being recognized and adopted into national frameworks around the world to improve patient care. Yet, there is still much to be done to ensure consistency in how these products are defined, regulated, evaluated, and funded,” explains Megan Coder, DTA Chief Policy Officer. “Understanding the current landscape is a first step towards establishing clear and consistent patient access pathways. This year, DTA is taking critical steps to build on this important foundation.”
These resources will help policymakers and DTx manufacturers understand commonalities and differences across jurisdictions, identify potential obstacles to overcome, and inform strategic approaches to ensure appropriate patient access to clinically-validated therapies. These pathways add to DTA’s collection of resources that broaden the understanding of DTx products across global regions, including a set of country-specific briefs that introduce digital therapeutics to patients, clinicians, payors, and policymakers in each country’s official language.
DTA Resource Partners, Health Advances and Eversana, were instrumental in developing these pathways, alongside DTA members, ANDHealth, and FlyingHealth. Through this and forthcoming initiatives, DTA looks forward to developing resources that enable patients, caregivers, clinicians, and policymakers to integrate, use, and benefit from DTx therapies.
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter.